Printer Friendly

MYCOGEN SIGNS INTERNATIONAL LICENSE AGREEMENT WITH KUBOTA

      MYCOGEN SIGNS INTERNATIONAL LICENSE AGREEMENT WITH KUBOTA
    SAN DIEGO, July 1 /PRNewswire/ -- Mycogen Corp. (NASDAQ: MYCO), a leader in the development of environmentally compatible biological pest control for agricultural crops, has announced the signing of an international licensing agreement with Kubota Corp.  The agreement, which provides for the commercialization of bioinsecticide products in Far East Asia and Japan, formalizes the existing research collaboration between Mycogen and Kubota.
    Under the terms of the agreement, Kubota will establish a subsidiary corporation which will be owned 60 percent by Kubota and 40 percent by Mycogen for the commercialization of bioinsecticides in Japan.  Mycogen will form a subsidiary corporation owned 60 percent by Mycogen and 40 percent by Kubota for the commercialization of bioinsecticides in the remainder of Far East Asia.  Mycogen retains product marketing rights elsewhere around the world.
    Additional terms call for the payment of a one-time licensing fee to Mycogen as well as additional research and development funding.
    Since 1989, Mycogen and Kubota have been field testing products in Far East Asia.  Registration is currently pending in Japan, Taiwan and Korea for MVP(R) bioinsecticide, the first product that will be commercialized in Far East Asia.
    "The establishment of the joint venture will enable Kubota and Mycogen to manage the development in their respective territories while sharing in the commercialization and economic benefits of the technology," said Jerry Caulder, Mycogen's chairman, president and chief executive officer.
    Mycogen provides crop protection products and services.  The company develops, manufactures and markets environmentally compatible products based on naturally occurring agents to control insects, parasites, weeds and other pests.  Mycogen develops its products through the application of genetic engineering techniques and innovative formulations.
    -0-                     7/1/92
    /CONTACT:  James R. Glynn, executive VP and CFO of Mycogen, 619-453-8030/
   (MYCO) CO:  Mycogen Corp. ST:  California IN: SU:  CON EH -- LA004 -- 5490 07/01/92 08:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1992
Words:311
Previous Article:MBAs TO MAKE HISTORY, NOT MONEY, IN EASTERN EUROPE
Next Article:QUAL-MED PURCHASES 34-STATE INSURANCE COMPANY
Topics:


Related Articles
MYCOGEN SIGNS INTERNATIONAL LICENSE AGREEMENT WITH KUBOTA
MYCOGEN ANNOUNCES SECOND QUARTER RESULTS
MYCOGEN'S MVP(R) BIOINSECTICIDE REGISTERED FOR COMMERCIAL SALE IN MEXICO
MYCOGEN'S MVP(R) BECOMES FIRST GENETICALLY ENGINEERED BIOPESTICIDE REGISTERED FOR COMMERCIAL SALE IN FRANCE
MYCOGEN, SCHERING-PLOUGH UNITS SIGN AGREEMENT TO MARKET BIOCONTROL PRODUCTS FOR POULTRY
MYCOGEN, SCHERING-PLOUGH UNITS SIGN AGREEMENT TO MARKET BIOCONTROL PRODUCTS FOR POULTRY
MYCOGEN, PIONEER JOIN FORCES TO DEVELOP PEST-RESISTANT CROPS
Dow Requests Amendment to Agreement With Mycogen

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters